Pharmacokinetic modelling of [2-13C]uracil metabolism in normal and DPD-deficient dogs.
A physiologically based pharmacokinetic (PBPK) model to simulate the plasma concentration and 13CO2 exhalation after [2-13C]uracil administration to DPD-suppressed dogs was developed. Simulation using this PBPK model should be useful in clinical situations where DPD-deficient patients at risk are to be detected with [2-13C]uracil as an in vivo probe.
Inada
M
M
Research Section, Diagnostics Division, Otsuka Pharmaceutical Co Ltd, Japan. inadam@otsuka.jp
Hirao
Y
Y
Koga
T
T
Itose
M
M
Kunizaki
J
J
Shimizu
T
T
Sato
H
H
D000284:Administration, Oral; D000818:Animals; D001944:Breath Tests; D002245:Carbon Dioxide / Q000737:chemistry; D002247:Carbon Isotopes / Q000378:metabolism*; D003198:Computer Simulation; D054067:Dihydropyrimidine Dehydrogenase Deficiency; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000096:biosynthesis* / Q000737:chemistry; D004285:Dogs; D007700:Kinetics; D008954:Models, Biological; D008956:Models, Chemical; D008962:Models, Theoretical; D013997:Time Factors; D014498:Uracil / Q000097:blood* / Q000737:chemistry* / Q000493:pharmacokinetics*
D002247:Carbon Isotopes; D002245:Carbon Dioxide; D014498:Uracil; D042943:Dihydrouracil Dehydrogenase (NADP)